BioVectra

What BioVectra does

BioVectra is a full-service contract development and manufacturing organization (CDMO) headquartered in Charlottetown, Prince Edward Island, Canada, with operations dating to 1970. The company provides clinical-to-commercial scale manufacturing services to the global pharmaceutical and biotechnology industry, with an enterprise-focused customer base that includes 18 of the top 20 global pharma and biotech companies. BioVectra serves more than 100 active clients across multiple geographies, earning revenue primarily through fee-for-service contract manufacturing agreements that span process development, analytical method development, GMP manufacturing, and fill-finish operations.

BioVectra's technology platform integrates four core manufacturing modalities: microbial fermentation (supporting recombinant proteins, plasmid DNA, and antibody fragments using BSL-1 systems including E. coli and Pichia pastoris), mammalian cell culture, complex synthetic chemistry for small molecule APIs, and aseptic fill-finish with capacity for up to 40,000 filled vials per day. The company also operates specialized HPAPI manufacturing capabilities with OELs down to 20 ng/m³ (SafeBridge Band 3 & 4), and end-to-end mRNA and plasmid DNA production capabilities including LNP formulation, integrated through a 36,000 sq ft mRNA Biomanufacturing Centre. Five GMP-certified facilities across Atlantic Canada anchor these capabilities, supported by strategic partnerships with Revolution Biomanufacturing (mRNA design) and Acuitas Therapeutics (LNP delivery technology).

The business operates on a project-based revenue model with multi-year supply contracts, where pricing is negotiated per project based on molecule complexity, manufacturing scale, and regulatory pathway. Distribution is exclusively through direct enterprise sales with dedicated business development teams engaging top-tier pharma and biotech clients. Following its September 2024 acquisition by Agilent Technologies for $925 million, BioVectra now operates as part of Agilent's Diagnostics and Genomics Group and serves as the foundation of Agilent Advanced Therapeutics, a unified CDMO platform launched in March 2026 that integrates BioVectra's Canadian operations with Agilent's Nucleic Acid Solutions in Colorado.

Name

BioVectra

Legal name

BIOVECTRA Inc.

Website

https://biovectra.com

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

501–1,000 employees

Short description

BioVectra is a Canadian full-service CDMO providing clinical-to-commercial scale contract manufacturing of biologics, small molecules, HPAPIs, mRNA/pDNA, and aseptic fill-finish products, serving 18 of the top 20 global pharmaceutical and biotechnology companies from five GMP facilities in Atlantic Canada, now operating within Agilent Advanced Therapeutics.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Contract manufacturing services
• Active pharmaceutical ingredients
• Biologics manufacturing
• Microbial fermentation services
• Aseptic fill-finish

Headquarters

HQ city

Charlottetown

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

1. Contract Manufacturing Services: BioVectra generates revenue primarily through fee-for-service contract manufacturing agreements. Customers engage BioVectra for specific stages of drug development and commercial production, including process development, analytical method development, GMP manufacturing, and fill-finish. Revenue is earned as services are rendered or upon milestone completion under long-term supply contracts. The model is project-based and recurring through multi-year client relationships.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

BioVectra is a full-service Contract Development and Manufacturing Organization (CDMO) providing clinical-to-commercial scale production of biologics, synthetic small molecules, plasmid DNA/mRNA, lipid nanoparticles (LNP), highly potent APIs (HPAPIs), bioreagents, and aseptic fill-finished drug products. The company operates five GMP manufacturing facilities across Atlantic Canada, leveraging microbial fermentation, mammalian cell culture, synthetic chemistry, and sterile fill-finish capabilities to serve global pharmaceutical and biotechnology clients.

Product overview

BIOVECTRA is a full-service CDMO (Contract Development and Manufacturing Organization) offering clinical-to-commercial scale production across multiple therapeutic modalities. The company operates as a unified platform with core capabilities including Biologics Manufacturing (microbial fermentation, recombinant proteins, pDNA, mRNA), Synthetic Small Molecules (complex chemistry, APIs), Highly Potent APIs (HPAPIs), Fermented Small Molecules, Bioreagents, Fill/Finish Services, and Gene Editing Manufacturing. Under the Agilent Advanced Therapeutics platform, BIOVECTRA provides end-to-end services from discovery through commercial manufacturing, supported by Project Support Services for process engineering, quality, and regulatory expertise. The company maintains 5 GMP facilities across Prince Edward Island and Nova Scotia, Canada, with specialized mRNA biomanufacturing capacity of 160 million doses per year.

Differentiator

Problem solved

Functional benefit

Products and services

• Biologics Manufacturing

Quantifiable outcome

• Serves 18 of the top 20 global pharmaceutical and biotechnology companies
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and supporting.

• Revolution BiomanufacturingcoreStrategic or Co-development Partner · 6 November 2025Strategic partnership enabling integrated mRNA design and GMP production services. The collaboration combines BioVectra's CDMO capabilities with Revolution Biomanufacturing's mRNA platform expertise, providing clients a streamlined path from mRNA design through GMP manufacturing. Announced November 6, 2025.
• Acuitas TherapeuticscoreStrategic or Co-development PartnerService agreement providing BioVectra clients access to Acuitas Therapeutics' industry-leading lipid nanoparticle (LNP) delivery system technology. This enables integrated mRNA development and delivery solutions for clients developing mRNA-based therapeutics and vaccines.
• CCRM, Cytiva (Precision Nanosystems), Northern RNA, OmniaBiosupportingStrategic or Co-development PartnerBioVectra is part of a Canadian ecosystem of advanced therapy partners including CCRM (cell and gene therapy), Cytiva/Precision Nanosystems (nanotechnology delivery), Northern RNA (RNA manufacturing), and OmniaBio (biologics and cell therapy manufacturing). Together, these organizations offer an integrated Canadian supply chain solution for immunotherapies and lentiviral vector development, reducing the need for Canadian biotech companies to seek manufacturing capabilities outside the country.

Scale indicators6 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• Lonza Group: Global CDMO leader offering microbial and mammalian biologics manufacturing, mRNA services, and fill-finish. Comparable as a full-service CDMO serving top-20 pharma with similar integrated modality breadth, though at significantly larger scale.
• Catalent: Major global CDMO with biologics, fill-finish, and nucleic acid manufacturing capabilities. Comparable in offering CDMO services across biologics modalities and serving large pharma; differs in its broader oral and softgel specialty franchise.
• Fujifilm Diosynth Biotechnologies: Large CDMO offering microbial and mammalian biologics, gene therapy, and vaccines manufacturing. Comparable in integrated biologics CDMO services with microbial fermentation expertise; larger scale and broader global footprint.
• WuXi Biologics: World's largest biologics CDMO with end-to-end microbial and mammalian services, including mRNA. Comparable CDMO offering across biologics modalities and top-20 pharma clients; significant pricing pressure on North American CDMOs.
• Samsung Biologics: Large-scale biologics CDMO with substantial mammalian cell culture capacity. Comparable in serving top-20 pharma with biologics manufacturing, but at much larger scale with different geographic footprint.

Direct peers

• AGC Biologics: Mid-to-large CDMO specializing in microbial and mammalian biologics, gene therapy, and mRNA manufacturing. Directly comparable to BioVectra in microbial fermentation focus and CDMO service model for biologics and nucleic acids.
• Recipharm: European-based CDMO offering biologics, fill-finish, and small molecule API manufacturing. Comparable as a full-service CDMO with similar project-based revenue model serving pharma clients, though with different geographic footprint.
• Rentschler Biopharma: CDMO specializing in microbial and mammalian cell culture-based biopharmaceuticals with aseptic fill-finish. Directly comparable to BioVectra's biologics core, with similar mid-tier scale and European-headquartered operations.
• Eurofins CDMO: European CDMO offering biologics, small molecule API, and HPAPI manufacturing services. Comparable as a mid-tier integrated CDMO with similar modality breadth and project-based revenue model.
• ten23 health: Swiss CDMO specializing in sterile injectable fill-finish and biologics manufacturing for challenging modalities. Comparable in aseptic fill-finish and biologics capabilities, particularly for small-to-mid-sized pharma clients seeking specialized services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Customer concentration

• LinkedInlinkedin.com/company/biovectra
• Xx.com/BioVectra

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioVectra